Patents for A61P 35 - Antineoplastic agents (221,099)
04/2004
04/06/2004US6716831 2,4-diamino-pyrimidine deprivatives having anti-cell proliferative activity
04/06/2004US6716828 Treatment or prevention of neural or cardiovascular tissue damage related to cerebral ischemia and reperfusion injury in an animal by administering poly(adp- ribose) polymerase (?parp?) inhibitors.
04/06/2004US6716825 Osteoporosis and other disorders of bone metabolisum, cancer, viral infections, and the like.
04/06/2004US6716821 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
04/06/2004US6716818 Caspase inhibitors and the use thereof
04/06/2004US6716623 Compositions and methods for identifying antigens which elicit an immune response
04/06/2004US6716585 Detecting genes associated with controlling angiogenesis; obtain and culture endothelial cells, isolate ribonucleic acids, amplified or reduced concentrations of preferenial ribonucleic acids indicate association with angiogenesis
04/06/2004US6716575 Diagnosis and treatment of AUR1 and/or AUR2 related disorders
04/06/2004CA2293672C Tricyclic keto amide derivatives useful as farnesyl protein transferase inhibitors
04/06/2004CA2087286C Thioether conjugates
04/06/2004CA2010321C Lymphocyte-associated cell surface protein
04/01/2004WO2004027421A2 Adp assay
04/01/2004WO2004027061A1 Method of screening remedy for proliferative disease
04/01/2004WO2004026897A1 Wt1 substitution peptides
04/01/2004WO2004026894A2 Synthesis and characterization of novel systems for guidance and vectorization of compounds having a therapeutic activity
04/01/2004WO2004026881A1 Macrocyclic pyrimidines, the production thereof and the use of the same as medicaments
04/01/2004WO2004026877A1 Imidazopyrazines as cyclin dependent kinase inhibitors
04/01/2004WO2004026874A1 Novel crystals of triazaspiro[5.5]undecane derivative
04/01/2004WO2004026873A1 Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
04/01/2004WO2004026872A1 Pyrazolopyridines as cyclin dependent kinase inhibitors
04/01/2004WO2004026871A1 Novel pyrazolopyridine derivatves as pharmaceutical agents
04/01/2004WO2004026867A2 Imidazopyridines as cyclin dependent kinase inhibitors
04/01/2004WO2004026865A1 Novel isothiazole and isoxazole compounds as transforming growth factor (tgf) inhibitors
04/01/2004WO2004026863A1 Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors
04/01/2004WO2004026859A1 Novel imidazole compounds as transforming growth factor (tgf) inhibitors
04/01/2004WO2004026851A1 3-(3,5-disubstituted-4-hydroxyphenyl)propionamide derivatives as cathepsin b inhibitors
04/01/2004WO2004026846A1 Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
04/01/2004WO2004026844A1 Methods and compositions of novel triazine compounds
04/01/2004WO2004026815A2 Phenol derivatives and their use as rotamase inhibitors
04/01/2004WO2004026407A1 Use of inhibitors of compounds involved in the jun kinase (jnk) biochemical cellular pathway for the treatment or diagnosis of liposarcomas
04/01/2004WO2004026341A1 Immunotherapeutic for cancer
04/01/2004WO2004026337A1 Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug
04/01/2004WO2004026325A2 Composition of berry extracts that prevents or inhibits angiogenesis and helicobacter pylori
04/01/2004WO2004026319A2 Pharmaceutical compositions increasing camp useful for the treatment of cancers
04/01/2004WO2004026311A2 Use of specific inhibitors of tyrosine kinases for immunomodulation
04/01/2004WO2004026307A1 Triazole derivatives as transforming growth factor (tgf) inhibitors
04/01/2004WO2004026306A2 Pyrazole derivatives as transforming growth factor (tgf) inhibitors
04/01/2004WO2004026304A1 An inhibitor of the shh signalling patway and a testosterone supressing agent for the treatment of cancer
04/01/2004WO2004026302A1 Methods of inhibiting tgf beta with substituted pyrazoles
04/01/2004WO2004026294A1 Leucine-enriched nutritional compositions
04/01/2004WO2004026293A2 Hemiasterlin derivatives for treating resistant tumors
04/01/2004WO2004026278A1 Copolymer and hemoprotein based novel compounds and uses thereof
04/01/2004WO2004026229A2 Pyrazolo[1,5-a]pyrimidines compounds as cyclin dependent kinase inhibitors
04/01/2004WO2004018681A3 Il-7 drug substance, il- 7 comprising composition, preparation and uses thereof
04/01/2004WO2004018475A3 Analogs of indole-3-carbinol metabolites as chemotherapeutic and chemopreventive agents
04/01/2004WO2004014928A3 Novel difluorinated gem compounds, preparation methods thereof and applications of same
04/01/2004WO2004009123A3 Gastrointestinal delivery of genetic material coupled to a transporting agent
04/01/2004WO2004007723A3 Genes
04/01/2004WO2004002476A9 Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
04/01/2004WO2003106659A3 Aptamer-toxin molecules and methods for using same
04/01/2004WO2003106498A3 Ox40 (=cd134) receptor agonistic and therapeutic use
04/01/2004WO2003106425A3 Phenyl- and pyridyl-diazaheterocycles having a tnf-modulating activity
04/01/2004WO2003103666A3 4,5-dihydro-imidazo[4,5,1-j] quinolin-6-ones as parp inhibitors
04/01/2004WO2003103644A3 Guanidino phenylalanin compounds used as urokinase inhibitors
04/01/2004WO2003101932A3 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
04/01/2004WO2003099771A3 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
04/01/2004WO2003097799A3 HTLV-I TAX INDUCED KILLING OF p53 NULL CANCER CELLS
04/01/2004WO2003097658A3 Compounds and methods for inhibiting selectin-mediated function
04/01/2004WO2003097633A8 2-thio-substituted imidazole derivatives and their use in pharmaceutics
04/01/2004WO2003097597A3 Indole derivatives and the use thereof as cb2 receptor ligands
04/01/2004WO2003095642A3 Polyepitopes and mini-genes for cancer treatment
04/01/2004WO2003091383A3 Epha2 antigen t epitopes
04/01/2004WO2003090737A3 Methods and compositions for treatment of cancer pain
04/01/2004WO2003090667A3 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
04/01/2004WO2003089449A3 Aminoalkyl sterol compounds having an anti-tumoral and neuroprotective activity
04/01/2004WO2003088927A3 Novel curcumin analogues and uses thereof
04/01/2004WO2003087840A3 Protein involved in cancer
04/01/2004WO2003084943A3 Terphenyl derivatives, preparation thereof, compositions containing same
04/01/2004WO2003084343A3 Method and dietary composition for improving fat digestibility
04/01/2004WO2003083124A3 Peptide epitopes common to antigens of the same multigene family
04/01/2004WO2003082875A3 Novel podophyllotoxin derivatives, the production thereof and the use of the same in therapeutics
04/01/2004WO2003082874A3 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-acetamide derivatives, preparation and use thereof in medicaments
04/01/2004WO2003081238A3 Cytocapacity test
04/01/2004WO2003077865A3 Methods and compositions for directing cells to target organs
04/01/2004WO2003077864A3 Methods and compositions for directing cells to target organs
04/01/2004WO2003075932A8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
04/01/2004WO2003074078A3 Cg3842 homologous proteins involved in the regulation of energy homeostasis
04/01/2004WO2003073828A3 Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
04/01/2004WO2003072821A3 Method and nucleic acids for the analysis of a colon cell proliferactive disorder
04/01/2004WO2003070886A3 Inhibition of protein tyrosine phosphatase type iva expression byshort interfering nucleic acid
04/01/2004WO2003067221A3 Compositions and methods for restoring immune responsiveness in patients with immunological defects
04/01/2004WO2003063792A3 Compositions and methods related to tim-3, a th1-specific cell surface molecule
04/01/2004WO2003063770A3 Expression vectors encoding epitopes of target-associated antigens and methods for their design
04/01/2004WO2003060090A3 Novel cytokine zcytor17 ligand
04/01/2004WO2003057012A8 S-dimethylarsino-thiosuccinic acid s-dimethylarsino-2-thiobenzoic acid s-(dimethylarsino) glutathione as treatments for cancer
04/01/2004WO2003049675A3 Treating muscle wasting with selective androgen receptor modulators
04/01/2004WO2003041642A3 Polymeric thiol-linked prodrugs employing benzyl elimination systems
04/01/2004WO2003031940A3 Structural and cytoskeleton-associated proteins
04/01/2004WO2003029282A3 Tumor-peptide antigens from the human prdi-bf1-protein
04/01/2004WO2003028652A3 Use of benzopyranones for treating or preventing a primary brain cancer or a brain metastasis
04/01/2004WO2003025019A8 Anti-pdgf antibodies and methods for producing engineered antibodies
04/01/2004WO2003009842A8 Injectable galenic formulation for use in a diagnosis or a photodynamic therapy and method for preparing same
04/01/2004WO2003008410A8 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
04/01/2004WO2002102314A3 Purine inhibitors of phosphodiesterase (pde) 7
04/01/2004WO2002098852A8 Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins
04/01/2004WO2002095417A3 PRE-mRNA SPLICING SCREENING ASSAY
04/01/2004WO2002085897A9 Heterocyclic compounds for aging-related and diabetic vascular complications
04/01/2004WO2002085286A3 Methods of using secondary lymphoid organ chemokine to modulate physiological processes in mammals
04/01/2004WO2002083847A3 Cdna encoding the human alpha2 delta4 calcium channel subunit
04/01/2004WO2002076402A3 Fatty amine drug conjugates